Theriva Biologics reports Q2 2025: VCN-01 Phase 2b success, cash $12.1M, runway into Q1 2026

Theriva Biologics, Inc.

2025-Q2 EPS reported -$3.64

Positive topline from VIRAGE Phase 2b: VCN-01 plus chemo improved OS, PFS, DOR vs chemo alone in metastatic pancreatic cancer.
Cash and cash equivalents $12.1M as of June 30, 2025; early Aug cash $9.5M, expected runway into Q1 2026.
G&A expenses $11.2M (up 662% YoY) due to $9.2M contingent consideration adjustment from VIRAGE success; R&D $2.0M (down 34%).
Expanded VIRAGE data to be presented at ESMO 2025 Congress in October.
Phase 1 retinoblastoma data of VCN-01 presented at ASCO 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.